Results 71 to 80 of about 260,886 (316)
Cancer Management and Research, 2020 Zixuan Gong,1,* Xiaoyu Chen,2,* YueChao Zhang,3,* Cheng Liu,4 Zhibing Wang,5 Xiaoyan Xu,6 Jun Zhu,7 Tongqing Xue4 1Department of Urology, Jiangsu Provincial People’s Hospital, Nanjing, Jiangsu Province, 211166, People’s Republic of China ...
Gong Z +7 more
doaj
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation
, 2017 Background: Epidermal growth factor receptor (EGFR) inhibitors show favorable clinical response in some patients with non-small cell lung cancer (NSCLC) who have no EGFR mutation, indicating alternative mechanisms for their tumoricidal effects.
余忠仁;陳昆鋒 +1 more
core +1 more source
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) [PDF]
, 2017 Lung cancer is the leading cause of cancer deaths worldwide. To date, the gold standard for the molecular analysis of a patient affected by NSCLC is the tissue biopsy.
Sober, L. +15 more
core +1 more source
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Cancer Reports, EarlyView., 2023 Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada +16 more
wiley +1 more source
, 2021 Context: Lung cancer is a type of cancer that causes the most deaths worldwide. The most common type of lung cancer is non-small cell lung cancer (NSCLC). Sea urchin (Arbacia lixula) has high potential as an antiNSCLC agent.
Ansori, Arif Nur Muhammad +6 more
core
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports [PDF]
, 2019 Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing 50% expression of programmed death-ligand 1 (PD-L1).
Bychkov, Andrey +7 more
core +1 more source
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
, 2021 Non-small cell lung cancer (NSCLC) is of major concern for society as it is associated with high mortality and is one of the most commonly occurring of all cancers. Due to the number of mutational variants and general heterogeneity of this type of cancer,
Munn, Alan L +4 more
core +1 more source
PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines
FEBS Open Bio, EarlyView.Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart +7 more
wiley +1 more source
, 2012 Non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer and has a 5 year survival rate of just 15%. Recently, tyrosine kinase inhibitors (TKIs) have been found to give dramatic therapeutic benefit to some patients increasing both their overall
Law, Tania Alice
core